drugset
drugset / Trial / NCT05500898

Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults

NCT05500898 ↗

Phase 1 Unknown 53 enrolled Daewoong Pharmaceutical Co. LTD.
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate drug-drug interaction by comparing the pharmacokinetics (PK)/pharmacodynamics (PD), safety, and tolerability of single/multiple doses of DWP16001 , DWC202204 and DWC202205 alone or in combination in healthy male adults.

Timeline

Start
2022-08-26
Primary completion
2022-10-31
Completion
2023-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject DWC202204 Unknown — Oral
Subject DWC202205 Unknown — Oral
Subject Enavogliflozin Small molecule — Oral

Indications

No indication recorded.